NASDAQ:NGNE Neurogene (NGNE) Stock Price, News & Analysis $37.31 +0.81 (+2.22%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$37.38 +0.07 (+0.20%) As of 07/17/2026 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Neurogene Stock (NASDAQ:NGNE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Neurogene alerts:Sign Up Key Stats Today's Range$35.05▼$38.2550-Day Range$26.14▼$42.8452-Week Range$15.93▼$43.66Volume473,344 shsAverage Volume293,275 shsMarket Capitalization$589.50 millionP/E RatioN/ADividend YieldN/APrice Target$84.83Consensus RatingBuy Company Overview Neurogene, Inc. is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions. Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues. Preclinical studies have demonstrated the potential for sustained biochemical correction and functional improvement, supporting the company’s progression into human clinical trials. Initial studies are under way in North America, and Neurogene plans to expand its clinical footprint into Europe pending regulatory clearances. Headquartered in South San Francisco, California, Neurogene was founded to address the unmet needs of patients and families living with life-threatening genetic disorders of the nervous system. The company’s executive leadership team brings together expertise in gene therapy development, neurology, and biopharmaceutical manufacturing. By targeting diseases with well-defined genetic causes and no approved treatments, Neurogene aims to deliver transformative therapies to patients worldwide.AI Generated. May Contain Errors. Read More Neurogene Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks67th Percentile Overall ScoreNGNE MarketRank™: Neurogene scored higher than 67% of companies evaluated by MarketBeat, and ranked 275th out of 848 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingBuy Consensus RatingNeurogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialNeurogene has a consensus price target of $84.83, representing about 127.4% upside from its current price of $37.31.Amount of Analyst CoverageNeurogene has only been the subject of 4 research reports in the past 90 days.Read more about Neurogene's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Neurogene are expected to grow in the coming year, from ($5.63) to ($5.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurogene is -8.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurogene is -8.20, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNeurogene has a P/B Ratio of 2.18. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Neurogene's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.02% of the float of Neurogene has been sold short.Short Interest Ratio / Days to CoverNeurogene has a short interest ratio ("days to cover") of 13.48, which indicates bearish sentiment.Change versus previous monthShort interest in Neurogene has recently decreased by 5.52%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNeurogene does not currently pay a dividend.Dividend GrowthNeurogene does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment1.14 News SentimentNeurogene has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Neurogene this week, compared to 3 articles on an average week. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Neurogene insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $639,932.00 in company stock.Percentage Held by Insiders11.68% of the stock of Neurogene is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.37% of the stock of Neurogene is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Neurogene's insider trading history. Receive NGNE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurogene and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. NGNE Stock News HeadlinesNeurogene (NGNE) Receives a Buy from LifeSci CapitalJuly 12, 2026 | theglobeandmail.comNeurogene (NASDAQ:NGNE) CFO Christine Mikail Cvijic Sells 600 SharesJuly 8, 2026 | insidertrades.comDon’t Buy SPCX Until You Read ThisSpaceX - ticker SPCX - just completed the biggest IPO in American history, raising $75 billion at a $1.8 trillion valuation. Goldman Sachs projects $474 billion in revenue by 2030, while Morgan Stanley goes further - $3.4 trillion by 2040. But NYU's Aswath Damodaran, Wall Street's 'Dean of Valuation,' called those projections 'a hallucination.' While every camera pointed at the rockets, Musk quietly placed a major bet on what he calls 'the world's biggest product' - something he believes could generate $30 trillion in revenue. Sixty of America's largest companies are making the same move, and the signal appeared in a quiet Friday SEC filing almost nobody noticed.July 18 at 1:00 AM | Porter & Company (Ad)Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 6, 2026 | businesswire.comInsider Selling: Neurogene (NASDAQ:NGNE) CFO Sells $25,170.34 in StockJuly 3, 2026 | insidertrades.comNeurogene: 'Hold' EMBOLDEN Study Underway And 2nd Half 2027 Topline DataJuly 2, 2026 | seekingalpha.comNeurogene bolsters cash runway with equity offeringJuly 2, 2026 | tipranks.comNeurogene Inc. Announces Pricing of $125 Million Public OfferingJuly 1, 2026 | finance.yahoo.comSee More Headlines NGNE Stock Analysis - Frequently Asked Questions How have NGNE shares performed this year? Neurogene's stock was trading at $20.60 at the beginning of the year. Since then, NGNE stock has increased by 81.1% and is now trading at $37.31. How were Neurogene's earnings last quarter? Neurogene Inc. (NASDAQ:NGNE) posted its quarterly earnings results on Tuesday, May, 12th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.30) by $0.09. When did Neurogene IPO? Neurogene (NGNE) raised $46 million in an initial public offering on Thursday, March 6th 2014. The company issued 4,200,000 shares at a price of $10.00-$12.00 per share. How do I buy shares of Neurogene? Shares of NGNE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Neurogene own? Based on aggregate information from My MarketBeat watchlists, some other companies that Neurogene investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), e.l.f. Beauty (ELF), Adobe (ADBE) and Disc Medicine (IRON). Company Calendar Last Earnings5/12/2026Today7/17/2026Next Earnings (Estimated)8/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 NGNE's financial health is in the Green zone, according to TradeSmith. NGNE has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NGNE Previous SymbolNASDAQ:NGNE CIK1404644 Webwww.neurogene.com Phone(877) 237-5020Fax778-331-4486Employees90Year Founded2018Price Target and Rating Average Price Target for Neurogene$84.83 High Price Target$180.00 Low Price Target$50.00 Potential Upside/Downside+127.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($4.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.35 million Net MarginsN/A Pretax MarginN/A Return on Equity-37.88% Return on Assets-34.70% Debt Debt-to-Equity RatioN/A Current Ratio13.08 Quick Ratio13.08 Sales & Book Value Annual Sales$930 thousand Price / Sales633.87 Cash FlowN/A Price / Cash FlowN/A Book Value$17.10 per share Price / Book2.18Miscellaneous Outstanding Shares15,800,000Free Float13,956,000Market Cap$589.50 million OptionableOptionable Beta1.68 Social Links 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NASDAQ:NGNE) was last updated on 7/18/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis tiny piece of glass could be bigger than GPUsJensen Huang says AI can't scale without it. Google Ventures calls it the future of AI compute. Sequoia Capita...Brownstone Research | SponsoredCentral banks bought 710 tonnes - this fund pays monthlyGold is hitting new highs, fueled by tariffs and record central bank demand - 710 tonnes per quarter. JPMorgan...Investors Alley | SponsoredBuy this stock todayMarc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...Chaikin Analytics | SponsoredElon’s message for AmericaElon Musk bought Super Bowl ad time at $266,000 per second - something he has never done before. 125 million A...Stansberry Research | SponsoredThe REAL Reason Trump is Invading IranFor a moment… Forget about Trump’s ties to Israel. Forget about reports of Iran’s nuclear program. Be...Banyan Hill Publishing | SponsoredEx-CIA Insider: “Prepare for a Mid-Term Meltdown”Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...Paradigm Press | SponsoredSPCX Warning - and Worst News for Stocks in 50 YearsGoldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neurogene Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neurogene With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
